Navigation Links
Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
Date:3/15/2010

e," "estimate," "expect," "intend," "plan," "will" and other similar expressions identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding the results of Savient's actions and efforts in support of its resubmission of the KRYSTEXXA™ (pegloticase)  BLA, the results of the reversion to and revalidation of the Phase 3 manufacturing process, whether the Company's third party contract manufacturing organization will successfully address the deficiencies and observations cited by the FDA at their facility, whether our BLA resubmission, combined with the submissions made and planned by our third party contract manufacturer, fully addresses the deficiencies and observations raised and provides the additional materials requested in the Complete Response Letter that we received from the FDA on July 31, 2009, which were further clarified in our meeting with the FDA on September 14, 2009, the timing of FDA action with respect to the resubmission, the efficacy and safety of KRYSTEXXA, potential FDA marketing approval for KRYSTEXXA and whether any further clinical trials will be required are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on our assessment and interpretation of the currently available data and information, our Phase 3 clinical data, our current understanding of the complete response letter and on current expectations, assumptions, estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to, the possibility that the FDA may raise further issues regarding the BLA for KRYSTEXXA or require that we conduct additional cl
'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
2. Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
3. Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
4. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
5. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
6. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
7. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
8. Savient Provides Update on Pegloticase BLA
9. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
10. U.S. Naval Medical Research Center Resubmits IND Application for Proposed RESUS Clinical Trial in Trauma Patients in the Out-of-Hospital Setting
11. U.S. Naval Medical Research Center Resubmits IND Application for Proposed Op RESUS Clinical Trial in Trauma Patients in the Battlefield Setting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015 Isis Pharmaceuticals, Inc. (Nasdaq: ... pro forma net operating loss (NOL) guidance and its ... position.  Isis, significantly improved financial results were due in ... payments the Company received from its partners.  Isis, pro ... nearly 60% improvement over its 2013 NOL of $40.2 ...
(Date:2/27/2015)... --  Synageva BioPharma Corp. (Synageva) (NASDAQ: ... products for rare diseases, joins the National Organization ... Rare Diseases™ (EURORDIS™), The Global Genes Project™, and ... Day. On the last day of ... participants conduct special events to raise awareness and ...
(Date:2/27/2015)... , February 27, 2015 ... sein bahnbrechendes Überwachungssystem für kongestive Herzinsuffizienz (CHF) ... -     ... die ein neuartiges Herzüberwachungssystem für Patienten mit ... bekannt, dass sie ein Finanzierungsvorhaben über 5 ...
Breaking Medicine Technology:Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2
... MOUNT PROSPECT, Ill., June 6, 2011 As part ... reducing abuse, misuse, and diversion of prescription medications, the ... development of the NABP PMP InterConnect. NABP will now ... (PMP) administrators and their software vendors to finalize the ...
... 2011 Cantel Medical Corp. (NYSE: CMN ... CEO of its Minntech Corporation subsidiary, sustained serious injuries ... Saturday evening. Mr. Malkin,s condition is currently ... Mr. Malkin,s treatment and recovery, division heads at Minntech ...
Cached Medicine Technology:NABP PMP InterConnect Development Complete; PMPs Continue to Sign on to Participate in National System for Tracking Drug Abuse and Diversion 2
(Date:2/27/2015)... (PRWEB) February 27, 2015 Legislation ... Committee, includes a pharmacy provision to help prevent ... the pharmacy counter. The Protecting the Integrity of ... Health Subcommittee Chairman Kevin Brady (R-TX) and Ranking ... address the prescription drug abuse epidemic and implement ...
(Date:2/27/2015)... The Dawn Greene Hospice, a 10-bed facility located ... on the Upper East Side, was officially dedicated and blessed ... Eminence Timothy Michael Cardinal Dolan. , Thomas J. Fahey, Jr., ... a member of the ArchCare Board of Trustees, presided over ... executive director of MMW, and Christina McInerney, president and CEO ...
(Date:2/27/2015)... February 27, 2015 Mediaplanet today announces ... Health,” a campaign that aims to bring blood health ... care conversation. The stories in this edition go beyond ... of clinical care, hard-hitting advocacy, research and technological strides ... According the American Cancer Society, approximately every 3 ...
(Date:2/27/2015)... Healthpointe is now performing arthroscopy ... or diseases affecting the elbow , wrist ... throughout Southern California, and are dedicated in providing ... related to the upper extremities. , Dr. ... board-certified and fully trained in treating an array ...
(Date:2/27/2015)... Dr. Christopher Saunders, a board certified plastic ... Chadds Ford, Pa., location. The spring special will run ... be priced at $3,950 with all fees included. , ... include more than $3,000 in MedSpa services offered at ... , Space is very limited, so those who are ...
Breaking Medicine News(10 mins):Health News:PCMA Statement on the ‘Protecting the Integrity of Medicare Act’ 2Health News:The Dawn Greene Hospice Is Officially Dedicated 2Health News:The Dawn Greene Hospice Is Officially Dedicated 3Health News:Know Your Blood: Raising Awareness through Mediaplanet’s “Blood Health” Campaign 2Health News:Healthpointe is Now Performing Arthroscopic Surgery Techniques for Elbow, Hand and Wrist Injuries and Diseases, such as certain Ganglion Cysts 2Health News:Dr. Christopher Saunders Announces Spring Breast Augmentation Special at $3,950 2Health News:Dr. Christopher Saunders Announces Spring Breast Augmentation Special at $3,950 3
... shot, study finds , , TUESDAY, March 24 (HealthDay News) -- ... the 1980s and 1990s contained DNA from human papillomavirus type ... study. , It also found that women diagnosed with HPV16- ... than those diagnosed with cancers associated with other HPV types. ...
... Human Cytomegalovirus Stimulates Telomerase Activity in Tissue Culture ... triggers expression of the telomerase reverse transcriptase (hTERT) ... cells grown in culture. , HCMV has been ... mechanism by which the virus acts has been ...
... 24 Dr. Janet Neigel and the staff at the ... much-anticipated May 3rd, Pre-Mother,s Day Open House. The Center, located ... Jersey, will open its doors on May 3rd, 2009 between ... healthy solutions to their various cosmetic needs. The Pre-Mother,s Day ...
... ate higher amounts of soy during childhood had a 58 ... published in Cancer Epidemiology, Biomarkers and Prevention , a ... breast cancer incidence rates have been four to seven times ... in China or Japan. However, when Asian women migrate to ...
... about the threat of tuberculosis and the toll it takes ... Day. , The TB-HIV co-infection crisis is twice as ... 2007, there were at least 1.37 million cases of HIV-positive ... double the previous WHO estimates. , "A global health ...
... Clinical Specialists to Present Clinical Experience at American Burn ... Nephew Inc,s Advanced Wound Management division (LSE: SN; NYSE: ... titled "Optimizing Outcomes in Burn Care" at the 41st ... this symposium, top burn specialists will present their clinical ...
Cached Medicine News:Health News:HPV Data May Aid Vaccine's Effectiveness 2Health News:Also in the March 24 JNCI 2Health News:Also in the March 24 JNCI 3Health News:Also in the March 24 JNCI 4Health News:Also in the March 24 JNCI 5Health News:Also in the March 24 JNCI 6Health News:Spring Forward with a New You! The Neigel Center for Cosmetic and Laser Surgery Hosts Its May 3rd Pre-Mother's Day Open House! 2Health News:Eating soy early in life may reduce breast cancer among Asian women 2Health News:Alarming new data shows TB-HIV co-infection a bigger threat 2Health News:Smith & Nephew Announces Symposium for Optimizing Outcomes in Burn Care 2Health News:Smith & Nephew Announces Symposium for Optimizing Outcomes in Burn Care 3Health News:Smith & Nephew Announces Symposium for Optimizing Outcomes in Burn Care 4
... CMC joint is the most common site for ... the CMC joint without restricting the wrist or ... persons who need to control or reduce subluxation ... perform work and leisure activities without pain. Also ...
... This is an excellent choice to treat ... MCP joint, basal joint arthritis, advanced carpal ... the thumb and wrist. Distal palmar ... flexion and full finger dexterity. Constructed ...
... CTi Wrist OTS is an off-the-shelf wrist orthotic designed ... of 3 pre-set ranges-of-motion (20°,35° and 50°). , ... sprains with TFCC tear-triangular fibrocartilage complex , ... nonunion , Partial tendon rupture , ...
... CTi Wrist Static is a solid, one-piece custom wrist ... stable, neutral position. , ,Indications: , Wrist ... fibrocartilage complex , Coles fracture - distal ... Partial tendon rupture , ORIF - Open ...
Medicine Products: